Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours Β· Estimated delivery Oct 7 - Oct 12
Aggressive simultaneous protocol (higher risk) Simultaneous start (both from week 1): Tirzepatide standard titration: Same as conservative: 2.5mg 12.5mg over 16 weeks Cagrilintide standard titration (parallel): Weeks 1-4: 0.6mg weekly Weeks 5-8: 1.2mg weekly Weeks 9-12: 1.8mg weekly Week 13+: 2.4mg weekly Aggressive dosing table: Why this is risky: Compounding side effects from start Very difficult to tolerate High dropout risk Unclear if any additional benefit Both hitting stomach simultaneously Potential maximum weight loss: 20-30% body weight (theoretical) Example: 240 lbs 168-192 lbs (48-72 lbs lost) But tolerability extremely questionable Who might attempt: Exceptional GI tolerance Prior success with GLP-1s without nausea Closely monitored by physician Willing to accept high side effect risk Can afford $1,200-2,400/month Understands experimental nature Lower cagrilintide doses with tirzepatide Moderate approach: Tirzepatide: Standard titration to 10-15mg Cagrilintide: Maximum 1.2-1.8mg (lower than standard 2.4mg) Rationale: Tirzepatide doing heavy lifting already Cagrilintide just adds amylin pathway Don't need maximum cagrilintide dose Better tolerability Significantly lower cost Moderate dosing comparison: Verdict: Lower cagrilintide doses (0.6-1.2mg) might be tolerable but benefit questionable
Providers can sign up for early access here: To view or add a comment, sign in Day 1 of the PCAC meeting brought encouraging progress, with BPC-157, KPV, TB-500, and MOTS-c recommended for inclusion on the 503A Bulks List
is a Professor Emerita, Departments of Physiology and Medicine at the University of Toronto, Toronto, ON, Canada
Depressive disorders and increased stress sensitivity are often associated with IBD, which might impact the progress and severity of the disorder
This is crucial as NF-B plays a pivotal role in regulating pro-inflammatory gene expression
